AI assistant
PTC THERAPEUTICS, INC. — Director's Dealing 2020
Nov 6, 2020
31046_dirs_2020-11-06_46ed3ddc-9592-4e7a-b246-d569ecac1e79.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2020-11-04
Reporting Person: Almstead Neil Gregory (Chief Technical Ops Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-11-04 | Common Stock | M | 2187 | $11.23 | Acquired | 29276 | Direct |
| 2020-11-04 | Common Stock | S | 2187 | $60 | Disposed | 27089 | Direct |
| 2020-11-04 | Common Stock | M | 21875 | $11.23 | Acquired | 48964 | Direct |
| 2020-11-04 | Common Stock | S | 21875 | $60 | Disposed | 27089 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | Stock Option (Right To Buy) | $11.23 | M | 2187 | Disposed | 2027-01-02 | Common Stock (2187) | Direct |
| 2020-11-04 | Stock Option (Right to Buy) | $11.23 | M | 21875 | Disposed | 2027-01-02 | Common Stock (21875) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right To Buy) | $490.8 | 2021-04-27 | Common Stock (216.0) | 216 | Direct |
| Stock Option (Right To Buy) | $218.4 | 2022-01-10 | Common Stock (166.0) | 166 | Direct |
| Stock Option (Right To Buy) | $27.05 | 2024-01-27 | Common Stock (40000.0) | 40000 | Direct |
| Stock Option (Right To Buy) | $51.0 | 2025-01-01 | Common Stock (69550.0) | 69550 | Direct |
| Stock Option (Right To Buy) | $30.86 | 2026-01-03 | Common Stock (55000.0) | 55000 | Direct |
| Stock Option (Right To Buy) | $18.01 | 2028-01-02 | Common Stock (70000.0) | 70000 | Direct |
| Stock Option (Right To Buy) | $33.02 | 2029-01-21 | Common Stock (72500.0) | 72500 | Direct |
| Stock Option (Right To Buy) | $33.02 | 2029-01-21 | Common Stock (17500.0) | 17500 | Direct |
| Stock Option (Right To Buy) | $51.16 | 2030-01-28 | Common Stock (69500.0) | 69500 | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on August 16, 2019.
F2: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
F3: Currently exercisable.
F4: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
F5: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F6: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F7: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.